Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||CBL Q249E|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|CBL mutant||myelodysplastic/myeloproliferative neoplasm||not applicable||N/A||Clinical Study||Prognostic||In clinical analyses, mutations in CBL were associated with adverse prognosis in patients with chronic myelomonocytic leukemia (PMID: 26230957, PMID: 23690417, PMID: 19901108).||26230957 19901108 23690417|
|CBL mutant||myelofibrosis||not applicable||N/A||Guideline||Prognostic||CBL mutations are associated with inferior overall survival in patients with primary myelofibrosis (NCCN.org).||detail...|
|CBL mutant||bone marrow cancer||sensitive||Quizartinib||Preclinical||Actionable||In a preclinical study, Quizartinib (AC220) reduced white blood cell counts and decreased myeloid cell invasion in a CBL mutant mouse model with myeloproliferative disorder (PMID: 22990016).||22990016|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|